Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.53 |
| ▸ | TNKS | O95271 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29460356 | 1.00 | KDR (1.00) | KDRCHEK1PDGFRBPDGFRATNKS | |
| SCHEMBL6166968 | 0.94 | KDR (0.89) | KDRCHEK1PDGFRBPDGFRATNKS | |
| SCHEMBL5076110 | 0.93 | KDR (0.86) | KDRCHEK1PDGFRBPDGFRATNKS | |
| SCHEMBL5081964 | 0.90 | KDR (0.81) | KDRCHEK1PDGFRBPDGFRA | |
| SCHEMBL5081988 | 0.87 | KDR (0.77) | KDRCHEK1PDGFRBPDGFRAFLT3 | |
| SCHEMBL5141013 | 0.87 | KDR (0.77) | KDRCHEK1PDGFRBPDGFRAAURKA | |
| SCHEMBL5078793 | 0.86 | KDR (0.75) | KDRCHEK1PDGFRBPDGFRAFLT3 | |
| SCHEMBL5079376 | 0.85 | KDR (0.74) | KDRCHEK1PDGFRBPDGFRA | |
| SCHEMBL5082515 | 0.84 | KDR (0.73) | KDRCHEK1PDGFRBPDGFRAAURKA | |
| SCHEMBL5078715 | 0.84 | KDR (0.72) | KDRCHEK1PDGFRBPDGFRAAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1328519-B1 | ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY | MERCK & CO INC (US) | 2005-09-07 | — | — | EP | claimed |
| EP-1328519-A4 | ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY | MERCK & CO INC (US) | 2004-12-15 | — | — | EP | claimed |
| US-20040002501-A1 | Orally active salts with tyrosine kinase activity | FRALEY MARK E (US) | 2004-01-01 | — | — | US | claimed |
| EP-1328519-A2 | ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY | Merck & Co., Inc. (US) | 2003-07-23 | — | — | EP | claimed |
| US-20020072526-A1 | Orally active salts with tyrosine kinase activity | MERCK & CO., INC. | 2002-06-13 | — | — | US | claimed |
| WO-2002032861-A2 | ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY | MERCK & CO., INC. (US) | 2002-04-25 | — | — | WO | claimed |
| US-20020041880-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2002-04-11 | — | — | US | claimed |
| US-20080274107-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-11-06 | — | — | US | disclosed |
| US-7186723-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-6960590-B2 | Orally active salts with tyrosine kinase activity | MERCK & CO. INC. (US) | 2005-11-01 | — | — | US | disclosed |
| EP-1328519-B1 | ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY | MERCK & CO INC (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20050096344-A1 | Tyrosine kinase inhibitors | FRALEY MARK E (US) | 2005-05-05 | — | — | US | disclosed |
| EP-1509254-A1 | NEW AGENTS FOR MAGNETIC IMAGING METHOD | Bracco Imaging S.p.A. (IT) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003103722-A1 | NEW AGENTS FOR MAGNETIC IMAGING METHOD | BRACCO IMAGING S.P.A. (IT) | 2003-12-18 | — | — | WO | disclosed |
| US-6656942-B2 | For therapy of diseases such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals | MERCK & CO., INC. | 2003-12-02 | — | — | US | disclosed |
| EP-1328519-A2 | ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY | Merck & Co., Inc. (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20020072526-A1 | Orally active salts with tyrosine kinase activity | MERCK & CO., INC. | 2002-06-13 | — | — | US | disclosed |
| WO-2002032861-A2 | ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY | MERCK & CO., INC. (US) | 2002-04-25 | — | — | WO | disclosed |
| US-20020041880-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2002-04-11 | — | — | US | disclosed |
| US-6306874-B1 | ENZYME INHIBITORS SUCH AS ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES, AND THE LIKE IN MAMMALS. | MERCK & CO., INC. | 2001-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002501-A1 | Orally active salts with tyrosine kinase activity | TEK, FLT1, TIE1 | KDR 5/4885CHEK1 989/4885PDGFRB 86/4885 |
| US-20020072526-A1 | Orally active salts with tyrosine kinase activity | TEK, FLT1, TIE1 | KDR 5/4885CHEK1 989/4885PDGFRB 86/4885 |
| US-20050096344-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885CHEK1 499/4885PDGFRB 88/4885 |
| US-20020041880-A1 | Method of treating cancer | ACP3, FOLH1, KLK3 | KDR 318/4885CHEK1 3711/4885PDGFRB 421/4885 |
| US-20080274107-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885CHEK1 499/4885PDGFRB 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.